vimarsana.com

21st Austria weekly - Valneva Vienna Stock Exchange 30/12/2022 [pic1]Valneva: an Austrian/French specialty vaccine company reported further heterologous booster data from exploratory small clinical study for its inactivated COVID-19 vaccine VLA2001. The show that a dose of VLA2001 was well tolerated in previously BNT162b2 Pfizer/BioNTech- or mRNA 1273 Moderna-vaccinated participants confirming the favorable safety profile seen across all studies – including homologous settings. However this study additional elicited only marginally increased neutralizing antibody response. Company positive results following primary vaccination with ChAdOx1-S AstraZeneca August

Related Keywords

Austria ,Vienna ,Wien ,Prague ,Praha ,Hlavníesto ,Czech Republic ,Russia ,Salzburg ,Ukraine ,Russian ,Austrian ,Christoph Boschan ,Prague Stock Exchange Group ,Vienna Stock Exchange , ,Stock Exchange ,Pierer Mobility ,Vienna Prague Stock Exchange Group ,Central European ,Mit Tochterunternehmen ,Besuchen Sie ,

© 2024 Vimarsana

vimarsana.com © 2020. All Rights Reserved.